Genzyme Sues Endo In Latest Renagel ANDA Suit
Genzyme Corp. has accused Endo Pharmaceuticals Inc. of infringing a patent for Renagel by seeking regulatory permission to sell a generic version of the kidney disease treatment in the U.S. before...To view the full article, register now.
Already a subscriber? Click here to view full article